1.01
3.81%
-0.0400
3.81%
-0.0400
(After Hours:
1.06
+0.0500
+4.95%)
NameNeubase Therapeutics
SectorHealthcare (1261)
IndustryBiotechnology (746)
Web
Phone646-450-1790
Employee8
Twitter
@NeuBaseInc
SEC filings
Latest SEC Filings
Next earning date2022-08-10
Address700 Technology Drive, Pittsburgh, PA, United States (15219)| Mar-22-22 07:01AM | Lannett And 4 Other Penny Stocks Bought By InsidersBenzinga |
| Feb-28-22 12:33PM | Tracking David Einhorn's Greenlight Capital Portfolio - Q4 2021 UpdateSeeking Alpha |
| Jan-11-22 08:20AM | The Daily Biotech Pulse: Illumina Announces Multiple Partnerships, Immunome Slides On Regulatory Setback For COVID Antibody Drug, Preannouncements Pour InBenzinga |
NeuBase Therapeutics, Inc., a biotechnology company, engages in the development of various antisense therapies to address genetic diseases in the United States. The company offers gene silencing therapies, including the proprietary PATrOL platform, a peptide-nucleic acid antisense oligonucleotide for genetic diseases caused by mutant proteins, including the Huntington's disease and myotonic dystrophy, as well as various other genetic disorders. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.
List of SPAC Stocks
List of EV Stocks and Related Stocks
Top 100 popular stocks on Robinhood
List of Marijuana Stocks
Cap:
|
Volume (24h):